Answers are grounded in this paper and cite their sources.
Background: Viral conjunctivitis, commonly known as pink eye, is a major cause of ocular morbidity. While mild cases typically resolve without intervention, severe cases require medical treatment due to signicant discomfort and potential complications. This study aims to evaluate the efcacy of topical steroids, which are often reserved for severe cases due to their potent antiinammatory effects, in the treatment of severe viral conjunctivitis. Methods: ial included 50 patients with severe viral conjunctivitis, divided into two groups. Group A received 0.5% Moxioxacin eye drops, 0.5% Carboxymethyl Cellulose eye lubricants, and cold compresses with oral analgesics as needed. Group B received the same treatment plus Loteprednol eye drops, a mild topical steroid. Treatment lasted for two weeks, with clinical reviews every three days to assess symptoms and monitor potential complications. There Results: was no signicant difference in the age and sex distribution between the groups. Discomfort levels assessed on a four-point scale showed signicant improvement in Group B over Group A on days 3 and 6 (p<0.001), suggesting an accelerated relief from symptoms. By day 14, both groups showed no signicant difference in discomfort levels, indicating that steroids do not alter the long-term course of the viral infection. Conclusion: The addition of topical steroids to the standard treatment regimen for severe viral conjunctivitis can signicantly improve shortterm symptomatic relief. However, they do not inuence the overall progression of the disease. This study supports the judicious use of steroids in severe cases, balancing efcacy with the potential for adverse effects.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: